Live Breaking News & Updates on Reliance Clinical Research Program

Stay updated with breaking news from Reliance clinical research program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today. ....

Sergio Traversa , Cedric Ogorman , Maged Shenouda , Tim Mccarthy , Securities Exchange , Goldman Sachs , Prnewswire Relmada Therapeutics Inc , Reliance Clinical Research Program , Relmada Therapeutics Inc , Chief Executive Officer , Chief Financial Officer , Cedrico Gorman , Chief Medical Officer , Goldman Sachs Global Healthcare Conference , Dana Point , Relmada Therapeutics , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act ,

Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference

/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today. ....

New York , United States , Maged Shenouda , Tim Mccarthy , Cedric Ogorman , Sergio Traversa , Relmada Therapeutics Inc , Reliance Clinical Research Program , Prnewswire Relmada Therapeutics Inc , Securities Exchange , Chief Executive Officer , Chief Financial Officer , Cedrico Gorman , Chief Medical Officer , Global Healthcare Conference , Global Healthcare , Relmada Therapeutics , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act ,

Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting

/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today. ....

United States , Coral Gables , Tim Mccarthy , American Society Of Clinical Psychopharmacology , Securities Exchange , Prnewswire Relmada Therapeutics Inc , Reliance Clinical Research Program , Relmada Therapeutics Inc , American Society , Clinical Psychopharmacology , Major Depressive Disorder , Inadequate Response , Standard Antidepressants , Abuse Potential , Withdrawal Signs , Symptoms From Esmethadone , Results From , Controlled Trial , Patients With Major Depressive , Relmada Therapeutics , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act ,

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Tim Mccarthy , Fabiana Fedeli , Sergio Traversa , Cedric Ogorman , Relmada Therapeutics Inc , Securities Exchange , Company Phase , Reliance Clinical Research Program , Company Board Of Directors , Relmada Therapeutics , Chief Executive , Chief Medical Officer , Chief Investment Officer Equities , Multi Asset , Anticipated Milestones , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Sci Advisors ,

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today. ....

United Kingdom , Tim Mccarthy , Sergio Traversa , Cedric Ogorman , Fabiana Fedeli , Company Board Of Directors , Relmada Therapeutics Inc , Securities Exchange , Company Phase , Reliance Clinical Research Program , Relmada Therapeutics , Chief Executive , Cedrico Gorman , Chief Medical Officer , Chief Investment Officer Equities , Multi Asset , Anticipated Milestones , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Sci Advisors ,